Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Anocca Raises $46M to Advance Clinical Trial Targeting Pancreatic Cancer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Anocca Raises $46M to Advance Clinical Trial Targeting Pancreatic Cancer

Financing supports the execution of early-stage clinical trials for Anocca’s lead program, VIDAR-1.

By: Rachel Klemovitch

Assistant Editor

Anocca AB (Anocca), a clinical-stage T-cell immunotherapy company, raised SEK ~440 million (USD ~46 million) in financing. Mellby Gård led the financing with strong support from AMF, Ramsbury, and existing shareholders, alongside new investors.

The additional capital will be used to drive the continued progress of VIDAR-1, Anocca’s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca’s preclinical pipeline.

Recruitment is now open for Phase I of the multi-center trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany, and the Netherlands.

Reagan Jarvis, co-founder and CEO of Anocca, said, “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics